Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	10,888	9,564	10,139	9,838	5,020
Short-Term Investments	-	-	-	53.53	1,875
Cash & Short-Term Investments	10,888	9,564	10,139	9,892	6,894
Cash Growth	13.84%	-5.67%	2.50%	43.48%	-51.39%
Accounts Receivable	8,915	10,134	10,508	9,914	8,693
Other Receivables	180	2,534	1,678	1,497	1,590
Receivables	9,106	12,676	12,197	11,426	10,294
Inventory	-	13,038	14,215	12,861	11,429
Prepaid Expenses	-	910	900	833.54	823.74
Other Current Assets	15,778	2,573	173	79.99	84.63
Total Current Assets	35,772	38,761	37,624	35,092	29,525
Property, Plant & Equipment	51,682	36,871	33,652	27,911	25,752
Long-Term Investments	435	422	2,564	2,386	2,541
Goodwill	25,410	24,639	24,286	22,428	21,300
Other Intangible Assets	10,967	10,433	9,510	9,263	8,006
Long-Term Deferred Tax Assets	2,574	2,327	2,275	1,613	1,547
Other Long-Term Assets	721	2,029	1,652	1,211	504.39
Total Assets	127,564	115,485	111,567	99,909	89,181
Accounts Payable	10,048	8,563	8,213	5,677	5,205
Accrued Expenses	-	3,293	2,786	3,091	2,846
Short-Term Debt	2,866	1,965	2,583	640	200.01
Current Portion of Long-Term Debt	-	505	414	3,994	-
Current Portion of Leases	556	521	534	521.93	501.34
Current Income Taxes Payable	184	370	624	345.06	468.11
Current Unearned Revenue	-	998	719	909.81	544.6
Other Current Liabilities	7,992	2,675	1,851	737.41	722.98
Total Current Liabilities	21,646	18,890	17,724	15,916	10,488
Long-Term Debt	21,503	31,671	31,104	24,642	25,640
Long-Term Leases	2,385	1,978	2,133	2,122	1,955
Long-Term Unearned Revenue	11,375	5,438	2,685	72.96	75.71
Long-Term Deferred Tax Liabilities	1,722	2,108	3,062	3,030	2,473
Other Long-Term Liabilities	6,547	647	459	445.45	602.28
Total Liabilities	65,178	61,274	57,649	46,745	41,766
Common Stock	158	158	159	159.28	159.28
Retained Earnings	-	45,397	45,368	46,860	43,187
Comprehensive Income & Other	62,391	8,784	8,466	6,166	4,069
Total Common Equity	62,549	54,339	53,993	53,186	47,415
Minority Interest	-163	-128	-75	-21.63	0.31
Shareholders' Equity	62,386	54,211	53,918	53,164	47,415
Total Liabilities & Equity	127,564	115,485	111,567	99,909	89,181
Total Debt	27,310	36,640	36,768	31,920	28,296
Net Cash (Debt)	-16,422	-27,076	-26,629	-22,028	-21,401
Net Cash Per Share	-103.40	-170.44	-167.32	-138.39	-134.37
Filing Date Shares Outstanding	158.19	158.35	159.07	159.17	159.17
Total Common Shares Outstanding	158.19	158.35	159.07	159.17	159.17
Working Capital	14,126	19,871	19,900	19,176	19,037
Book Value Per Share	395.41	343.16	339.43	334.14	297.88
Tangible Book Value	26,172	19,267	20,197	21,495	18,109
Tangible Book Value Per Share	165.45	121.67	126.97	135.04	113.77
Land	-	444	440	447.86	436.86
Buildings	-	8,622	8,498	7,957	7,744
Machinery	-	32,484	29,213	26,009	21,826
Construction In Progress	-	12,523	7,733	2,918	2,778

Source: S&P Global Market Intelligence. Standard template. Financial Sources.